Coherus Oncology, Inc. SEC filings CHRS
Coherus Oncology, Inc. has 921 filings in SEC EDGAR's recent list, going back to Feb 23, 2011. Its latest annual report, Form ARS, was filed on Apr 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 8, 2025 | — |
| CORRESP | Letter to the SEC | Dec 5, 2025 | — |
| SC TO-I/A | Filing | May 15, 2025 | — |
| SC TO-I | Filing | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2024 | — |
| CORRESP | Letter to the SEC | Sep 6, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2024 | — |
| EFFECT | Filing | Jul 26, 2023 | — |
| CORRESP | Letter to the SEC | Jul 24, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| 425 | Filing | Jun 16, 2023 | — |
| EFFECT | Filing | Nov 17, 2022 | — |
| CORRESP | Letter to the SEC | Nov 15, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2022 | — |
| CORRESP | Letter to the SEC | Apr 20, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2022 | — |
| CORRESP | Letter to the SEC | Dec 30, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2021 | — |
| CT ORDER | Filing | May 12, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2019 | — |
| CORRESP | Letter to the SEC | Nov 6, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2019 | — |
| CORRESP | Letter to the SEC | Oct 15, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2019 | — |
| CT ORDER | Filing | Aug 20, 2018 | — |
| CT ORDER | Filing | Jun 21, 2018 | — |
| EFFECT | Filing | May 7, 2018 | — |
| CORRESP | Letter to the SEC | May 4, 2018 | — |
| CORRESP | Letter to the SEC | Mar 27, 2018 | — |
| CORRESP | Letter to the SEC | Mar 22, 2018 | — |
| CORRESP | Letter to the SEC | Feb 16, 2018 | — |
| CORRESP | Letter to the SEC | Feb 14, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2018 | — |
| CT ORDER | Filing | Dec 14, 2017 | — |
| D | Filing | Dec 13, 2017 | — |
| EFFECT | Filing | Oct 16, 2017 | — |
| CORRESP | Letter to the SEC | Oct 11, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 28, 2017 | — |
| CT ORDER | Filing | Aug 22, 2017 | — |
| CT ORDER | Filing | Sep 30, 2016 | — |
| EFFECT | Filing | Jan 21, 2016 | — |
| CORRESP | Letter to the SEC | Jan 19, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2015 | — |
| CT ORDER | Filing | Oct 6, 2015 | — |
| D | Filing | Sep 17, 2015 | — |
| CT ORDER | Filing | Jul 16, 2015 | — |
| CT ORDER | Filing | Apr 7, 2015 | — |
| EFFECT | Filing | Mar 31, 2015 | — |
| EFFECT | Filing | Nov 6, 2014 | — |
| CT ORDER | Filing | Nov 6, 2014 | — |
| CERTNAS | Auto-generated paper document | Nov 5, 2014 | — |
| 8-A12B | Filing | Nov 3, 2014 | — |
| CORRESP | Letter to the SEC | Nov 3, 2014 | — |
| CORRESP | Letter to the SEC | Oct 7, 2014 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2014 | — |
| DRS/A | Filing | Sep 24, 2014 | — |
| DRSLTR | Filing | Sep 15, 2014 | — |
| DRS/A | Filing | Sep 15, 2014 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2014 | — |
| DRS/A | Filing | Aug 5, 2014 | — |
| DRS | Filing | Aug 4, 2014 | — |
| D | Filing | Jun 4, 2014 | — |
| D | Filing | Jul 24, 2013 | — |
| D | Filing | Jan 14, 2013 | — |
| D/A | Filing | Jan 3, 2012 | — |
| D | Filing | Jul 25, 2011 | — |
| D | Filing | Mar 10, 2011 | — |
| D | Filing | Feb 23, 2011 | — |
Showing 76 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CHRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1512762
- Former names
- Coherus BioSciences, Inc. (until May 28, 2025); BioGenerics, Inc. (until Jan 3, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.